Navigation Links
Long-term use of diabetes drugs by women significantly increases risk of fractures
Date:12/9/2008

A group of drugs commonly used to treat diabetes can double the risk of bone fractures in women, according to a new study by the University of East Anglia (UEA) and Wake Forest University.

Published today in the Canadian Medical Association Journal (CMAJ), the findings show that use of thiazolidinediones for more than one year by women with type 2 diabetes significantly reduces bone density, resulting in the risk of fractures being doubled.

The researchers found no increased risk of fractures among men, however.

Thiazolidinediones are a group of drugs used to treat type 2 diabetes. Included in this group are the drugs rosiglitazone and pioglitazone. Latest figures show there are around 4 million users of these drugs in the US, while in the UK there were around 2 million prescriptions for rosiglitazone and pioglitazone last year.

"Women with type 2 diabetes are already at an increased risk of fractures - with a near doubling in the risk of hip fractures - so any additional risk from thiazolidinedione therapy could have a considerable impact on public health," said lead author Dr Yoon Loke, of the University of East Anglia.

"The underlying causes of this gender-specific effect of thiazolidinediones require further investigation. In the meantime, regulatory authorities and clinicians should reconsider recommending these drugs to women with type 2 diabetes.

"This is a problem that arises with long-term use, and patients should not stop or change their treatment suddenly without consulting their doctors. Women who have taken these drugs for more than a year should speak to their doctors about other treatment options."

Recent research into thiazolidinediones has focussed on the drugs' adverse cardiovascular effects. This new meta-analysis involved a systematic review of 10 clinical trials involving a total of 13,715 participants. The trials lasted from one to four years and all were double-blinded.

There is no clear evidence that other drugs used to treat type 2 diabetes, such as metformin and sulfonylurea, cause an increased risk of fractures.


'/>"/>

Contact: Simon Dunford, Press Officer
s.dunford@uea.ac.uk
44-016-035-92203
University of East Anglia
Source:Eurekalert

Related biology news :

1. European biodiversity and ecosystem scientists merge and gear up for long-term research
2. Exposing chicks to maternal stress leads to long-term reproductive success
3. Birth control has long-term effect on hormone exposure
4. Long-term study shows effect of climate change on animal diversity
5. Dioxin risk in soil and plant tissues after long-term biosolids application
6. Aerosol toxins from red tides may cause long-term health threat
7. Long-term study of middle-aged mice shows
8. Dont count on long-term success in climate policy, warns paper in Decision Analysis
9. Study of marine snail leads to new insights into long-term memory
10. Cancer immunotherapy shows long-term promise in lung cancer
11. New vaccine may give long-term defense against deadly bird flu and its variant forms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... DIEGO and NEWARK, Del. ... , a privately-held regenerative medicine company, and W. ... materials science company, today announced a collaborative research agreement ... novel implantable cell therapy delivery device technologies that provide ... than a decade, ViaCyte has been developing innovative stem ...
(Date:3/29/2017)... /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") ... risk stratification test for breast cancer, via its ... BreastSentry incorporates a blood-based biomarker test with a sophisticated algorithm ... breast cancer.   ... BreastSentry measures the fasting plasma levels of two ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, ... and comprehensive study on the existing state of the global Microfluidic ... Europe and Asia-Pacific , ... and Africa . ... Browse 172 Tables and Figures, 13 Major Company ...
(Date:3/28/2017)... Hong Kong (PRWEB) , ... March 28, 2017 ... ... has selected NetDimensions Learning to replace paper-based processes and enhance training plan management ... “We are very pleased to partner with the SHL Group to help improve ...
Breaking Biology Technology: